These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1072 related articles for article (PubMed ID: 21763935)

  • 1. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
    Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
    Behrens G; Rijnders B; Nelson M; Orkin C; Cohen C; Mills A; Elion RA; Vanveggel S; Stevens M; Rimsky L; Thorpe D; Bosse M; White K; Zhong L; DeMorin J; Chuck SK
    AIDS Patient Care STDS; 2014 Apr; 28(4):168-75. PubMed ID: 24660840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
    ; Carey D; Puls R; Amin J; Losso M; Phanupak P; Foulkes S; Mohapi L; Crabtree-Ramirez B; Jessen H; Kumar S; Winston A; Lee MP; Belloso W; Cooper DA; Emery S
    Lancet Infect Dis; 2015 Jul; 15(7):793-802. PubMed ID: 25877963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials.
    Molina JM; Clumeck N; Orkin C; Rimsky LT; Vanveggel S; Stevens M;
    HIV Med; 2014 Jan; 15(1):57-62. PubMed ID: 23980523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
    Nelson MR; Elion RA; Cohen CJ; Mills A; Hodder SL; Segal-Maurer S; Bloch M; Garner W; Guyer B; Williams S; Chuck S; Vanveggel S; Deckx H; Stevens M
    HIV Clin Trials; 2013; 14(3):81-91. PubMed ID: 23835510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
    Domingo P; Ribera E
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.
    Cohen CJ; Molina JM; Cahn P; Clotet B; Fourie J; Grinsztejn B; Wu H; Johnson MA; Saag M; Supparatpinyo K; Crauwels H; Lefebvre E; Rimsky LT; Vanveggel S; Williams P; Boven K; ;
    J Acquir Immune Defic Syndr; 2012 May; 60(1):33-42. PubMed ID: 22343174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.
    Mills AM; Antinori A; Clotet B; Fourie J; Herrera G; Hicks C; Madruga JV; Vanveggel S; Stevens M; Boven K;
    HIV Med; 2013 Aug; 14(7):391-400. PubMed ID: 23298380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE.
    Hodder S; Arasteh K; De Wet J; Gathe J; Gold J; Kumar P; Mohapi L; Short W; Crauwels H; Vanveggel S; Boven K
    HIV Med; 2012 Aug; 13(7):406-15. PubMed ID: 22416849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis.
    Molina JM; Clumeck N; Redant K; Rimsky L; Vanveggel S; Stevens M;
    AIDS; 2013 Mar; 27(6):889-897. PubMed ID: 23276806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
    Lennox JL; DeJesus E; Lazzarin A; Pollard RB; Madruga JV; Berger DS; Zhao J; Xu X; Williams-Diaz A; Rodgers AJ; Barnard RJ; Miller MD; DiNubile MJ; Nguyen BY; Leavitt R; Sklar P;
    Lancet; 2009 Sep; 374(9692):796-806. PubMed ID: 19647866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial.
    Wilkin A; Pozniak AL; Morales-Ramirez J; Lupo SH; Santoscoy M; Grinsztejn B; Ruxrungtham K; Rimsky LT; Vanveggel S; Boven K;
    AIDS Res Hum Retroviruses; 2012 May; 28(5):437-46. PubMed ID: 21902621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
    Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
    Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
    Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S;
    Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.
    Rimsky L; Van Eygen V; Hoogstoel A; Stevens M; Boven K; Picchio G; Vingerhoets J
    Antivir Ther; 2013; 18(8):967-77. PubMed ID: 23714781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials.
    Cohen CJ; Molina JM; Cassetti I; Chetchotisakd P; Lazzarin A; Orkin C; Rhame F; Stellbrink HJ; Li T; Crauwels H; Rimsky L; Vanveggel S; Williams P; Boven K;
    AIDS; 2013 Mar; 27(6):939-950. PubMed ID: 23211772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rilpivirine. First-line treatment of HIV infection: efavirenz is better documented.
    Prescrire Int; 2012 Nov; 21(132):262-5. PubMed ID: 23210255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
    Tebas P; Sension M; Arribas J; Duiculescu D; Florence E; Hung CC; Wilkin T; Vanveggel S; Stevens M; Deckx H;
    Clin Infect Dis; 2014 Aug; 59(3):425-34. PubMed ID: 24729492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.